| Recent advances in inflammasome biology |
51 |
| Plasticity of myeloid-derived suppressor cells in cancer |
49 |
| Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering |
35 |
| NKG2D and its ligands in cancer |
27 |
| Chemokines and cancer: new immune checkpoints for cancer therapy |
24 |
| Innate effector cells in angiogenesis and lymphangiogenesis |
23 |
| Ion channelopathies of the immune system |
22 |
| Induction of innate immune memory: the role of cellular metabolism |
22 |
| Strategies for a multi-stage neutralizing antibody-based HIV vaccine |
21 |
| Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections |
20 |
| The NLRP1 inflammasome: new mechanistic insights and unresolved mysteries |
18 |
| The evolving role of lymphatics in cancer metastasis |
18 |
| Oncolytic viruses and immunity |
18 |
| IL-6: a cytokine at the crossroads of autoimmunity |
17 |
| Metals as phagocyte antimicrobial effectors |
16 |
| Regulation of MAVS activation through post-translational modifications |
16 |
| Natural killer cell education in human health and disease |
16 |
| Cytosolic sensing of immuno-stimulatory DNA, the enemy within |
16 |
| Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control |
15 |
| Myeloid derived-suppressor cells: their role in cancer and obesity |
15 |
| The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses |
15 |
| Transcriptional programming of tissue-resident memory CD8(+) T cells |
15 |
| When designing vaccines, consider the starting material: the human B cell repertoire |
14 |
| New roles and controls of mast cells |
14 |
| Mass cytometry: a powerful tool for dissecting the immune landscape |
14 |
| Antiviral RNA interference in mammals |
13 |
| Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism |
13 |
| LC3-associated phagocytosis: host defense and microbial response |
13 |
| Driving CARs on the uneven road of antigen heterogeneity in solid tumors |
13 |
| Adoptive T cell therapy: points to consider |
13 |
| Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness |
13 |
| Developmental control of macrophage function |
13 |
| Multiple roles of lymphatic vessels in tumor progression |
12 |
| Vaccine options for influenza: thinking small |
12 |
| Disease tolerance: concept and mechanisms |
12 |
| Modulation of innate and adaptive immunity by P2X ion channels |
12 |
| Innate immunosensing of DNA in cellular senescence |
12 |
| The regulation of lymphocyte activation and proliferation |
12 |
| Mast cells and basophils in allergic inflammation |
12 |
| The hygiene hypothesis: immunological mechanisms of airway tolerance |
12 |
| Pertussis vaccines and protective immunity |
11 |
| Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation |
11 |
| P2X receptor-ion channels in the inflammatory response in adipose tissue and pancreas potential - triggers in onset of type 2 diabetes? |
10 |
| Zika virus vaccines: immune response, current status, and future challenges |
10 |
| Harnessing immune history to combat influenza viruses |
10 |
| ILC2s-resident lymphocytes pre-adapted to a specific tissue or migratory effectors that adapt to where they move? |
10 |
| Cellular pathways in the development of human and murine innate lymphoid cells |
10 |
| Host inflammasome defense mechanisms and bacterial pathogen evasion strategies |
10 |
| The phagocyte NOX2 NADPH oxidase in microbial killing and cell signaling |
10 |
| Bridging the gap between vaccination with Bacille Calmette-Guerin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis |
10 |
